Navigation Links
Home-based Self-collected Vaginal Specimens Detect More Cervical Lesions and Cancers Than Cytology

HILDEN, Germany and GAITHERSBURG, Maryland, November 2, 2011 /PRNewswire/ --

- Vaginal Self-collection for Hybrid Capture®-based HPV Testing Increases Screening Coverage and is More Sensitive than Pap Smear Shows a Mexican Study Published Today Online in the Lancet

Promising findings published today online in the Lancet[1] from a community-based, randomized equivalence trial undertaken by public health authorities in Mexico to investigate DNA home testing for human papillomavirus (HPV) compared with cytology (evaluation of cells) based on Pap smears. The study indicated that the relative sensitivity of HPV molecular testing was 3.4 times higher than cytology. Additionally, 4.2 times more invasive cancers were detected. The home testing study adds support to previous evidence[2] that adding self-collection to the screening setup can increase the coverage rate of cervical cancer prevention programs, especially in underserved regions in developing and developed countries. The study was funded by the Instituto Nacional de Salud Pública (INSP), the Health Ministry of Mexico and QIAGEN.

"HPV testing is lower in cost, easier to implement, and has lower false-negative rates than cytology. Testing of self-collected vaginal samples offers increased coverage and acceptability," commented the lead study author, Dr. Eduardo Lazcano-Ponce, professor at the Centro de Investigación en Salud Poblacional of INSP in Morelos, Mexico.

The trial included 25,061 women of low socioeconomic status between 26 to 65 years from 540 rural communities in Morelos, Guerrero, and Mexico State, Mexico. They were randomly allocated to HPV DNA testing of a vaginal sample self-collected at home or cervical cytology at the nearest health center. Eight community nurses visited the self-collection women at home and instructed them how to use the digene® cervical sampler, a conical-shaped brush, to take the sample. The study used the digene® HPV test based on Hybrid Capture 2, which is considered the gold standard for HPV testing and already has been clinically validated in trials including more than one million women worldwide. The primary endpoint was CIN2 or worse, detected by colposcopy. Any woman having a positive result for either of the tests was referred to colposcopy.

The participation rate was higher in women randomized to the HPV group (9,202 of 9,371, 98%) than in the cytology group (11,054 of 12,731, 87%). Importantly, in the HPV group more invasive cancers were detected than with cytology (28 vs. 8). With a lower positive predictive value for HPV testing (PPV CIN2 or worse 12.2% vs. 90.5%) the identification of appropriate triage methods is crucial. The study adds: "Because women at these sites will be screened only a few times in their lives, the high sensitivity of a HPV screen is of paramount importance."

Based on data from several national trials including Hybrid Capture technology, Mexico is the first country to implement frontline HPV testing with cytology triage as a national cervical cancer prevention program. Dr. Nubia Munoz, Colombian Cancer Institute, Bogota, Colombia, and Dr. Rolando Herrero, Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France, conclude in an accompanying editorial in the Lancet: "The experience shows what can be achieved when scientific judgment guides public health policy."

"The value of HPV DNA testing in cervical cancer screening and disease detection has been proven again and again for both the developed and developing worlds. Self-collection for HPV DNA testing could become an important way for national cervical cancer prevention programs worldwide to increase coverage rates," said Dr. Helge Lubenow, Head of the Molecular Diagnostic Business at QIAGEN. "Our digene HPV testing solutions have been used in several trials for self-collection, and we support any approach that helps to include populations that are difficult to reach as here are most cases of cancer to be found."

About cervical cancer and the digene® HPV test

Worldwide, cervical cancer affects approximately 500,000 women annually and, after breast cancer, is the second-most-common malignancy found in women. Since the cause of cervical cancer - HPV - is known and women who have it can be identified, it is a highly preventable and treatable disease if women have access to organized prevention programs. The World Health Organization estimates that only about five percent of women in the developing world have been screened for cervical disease in the previous five years compared to 75 percent in the developed world. In the U.S., the digene HPV Test is approved for use together with a Pap test in women 30 years and older. In Europe, it is approved as an initial general population screening test either alone or together with a Pap test. It is also used as a follow-up to inconclusive Pap test results. For more information about HPV and cervical cancer, visit

About self-collected samples

HPV testing offers the ability for women to self-collect a specimen that can be sent to a laboratory for testing; this cannot be done with a pap smear. Specimens are self-collected in either a clinical setting or in a home. Several health authorities, e.g. in the Netherlands and Mexico, have already investigated the effectiveness of self-collected specimens to determine if it could increase the coverage and effectiveness of their cervical cancer screening program and reach women who today are unscreened. Trials in both countries have shown very promising results and both have used the digene HPV test as the test for screening. Therefore, self-collection could be a useful addition to cervical cancer screening programs and when new algorithms are implemented that incorporate HPV DNA testing. This is true for both developing countries as well as in the developed world. Currently the digene HPV test is validated using digene Cervical Sampler and is not validated for use with self-collected specimens.


QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs about 3,700 people in over 35 locations worldwide. Further information about QIAGEN can be found at

1. Lazcano-Ponce, E. et al. (2011) Self-collection of vaginal specimens for human papillomavirus testing in cervical prevention (MARCH): a community-based randomised controlled trial. Lancet 378. Published Online November 2, 2011 DOI:10.1016/S0140-6736(11)61522-5.

2. Gök, M. et al. (2011) Experience with high-risk human papillomavirus testing on vaginal brushbased self-samples of non-attendees of the cervical screening program. Int J Cancer. doi: 10.1002/ijc.26128.

QIAGEN Media Contacts:

Svea Lübcke                        
Associate Director Marketing PR                   

Shelley Ducker
Associate Director of Communications

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens
2. Norgen Biotek Corp. Launches a Novel kit to Collect, Concentrate, Preserve and Isolate DNA, RNA, microRNA and proteins from Urine Specimens
3. Low-cost paper-based wireless sensor could help detect explosive devices
4. Biosensing tool to detect salmonella holds promise for preventing common food poisoning
5. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
6. Sheffield scientists shine a light on the detection of bacterial infection
7. Cancer detection from an implantable, flexible LED
8. Scientists utilize breath and sweat to detect trapped humans
9. Nanowire-based sensors offer improved detection of volatile organic compounds
10. Nano detector for deadly anthrax
11. Molecular Detection Inc. and Eldan Electronic Instruments Announce Distribution Agreement for Detect-Ready® MRSA Panel in Israel
Post Your Comments:
(Date:11/30/2015)... Partnership includes an MPP ... the u niversity , s Solid Drug Nanoparticle (SDN) ... - up through cost cuts ... , where licensees based anywhere in the world will have the right to make, ... Africa , where licensees based anywhere in the world will have the right ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... touring exhibition Jurassic World: The Exhibition, opening in March 2016 at Melbourne Museum ... a worldwide tour including several North American tour dates. The Exhibition is based ...
(Date:11/30/2015)... , Nov. 30, 2015  Aytu BioScience, Inc. (OTCQB: ... and related conditions, will present at two upcoming investor ... an interactive real-time virtual conference, to be held December ... Conference, to be held December 2 nd & ... and streamed live via webcast. ...
(Date:11/30/2015)... TIKVAH, Israel , Nov. 30, 2015 /PRNewswire/ ... a leading developer of adult stem cell technologies for neurodegenerative ... Ltd., has been awarded an additional grant of approximately $735,000 ... Scientist (OCS). This grant, the second this year, brings the ... approximately $1.8 million (approximately NIS7 million).  ...
Breaking Biology Technology:
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):